Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin

Journal of Internal Medicine

Volumn 252, Issue 5, 2002, Pages 430-439

  Malmqvist, Karin ^a   Ohman K P ^b,c   Lind, L ^d   Nystrom F ^b   Kahan, T ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood pressure; Catecholamines; Insulin; Left ventricular hypertrophy; Leptin; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; CATECHOLAMINE DERIVATIVE; GLUCOSE; INSULIN; LEPTIN; NEUROHORMONE; NORADRENALIN; PROINSULIN; RENIN; CATECHOLAMINE;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BODY SIZE; CELL GROWTH; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION; BLOOD; HEART RATE; HOMEOSTASIS; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CATECHOLAMINES; ECHOCARDIOGRAPHY; FEMALE; HEART RATE; HOMEOSTASIS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INSULIN; LEPTIN; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 0036878284     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.01053.x     Document Type: Article

References (56)

1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-41.
2. Devereux R. Hypertensive cardiac hypertrophy: pathophysiological and clinical characteristics. In: Laragh JH, Brenner BM eds. Diagnosis and Management. New York: Ravens Press, 1995: 409-32.
3. Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension 1987; 9: 1153-60.
4. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
6. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-54.
7. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993; 88 (Suppl. 1): 107-24.
8. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35; 985-91.
9. Julius S, Majahalme S. The changing face of sympathetic overactivity in hypertension. Ann Med 2000; 32: 365-70.
10. Esler M. The relation of human cardiac sympathetic nervous activity to left ventricular mass: commentary. J Hypertens 1996; 14: 1365-7.
11. Patel MB, Stewart JM, Loud AV et al. Altered function and structure of the heart in dog with chronic elevation in plasma norepinephrine. Circulation 1991; 84: 2091-100.
12. Kelm M, Schafer S, Mingers S et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14: 1357-64.
13. Hill DJ, Milner RD. Insulin as a growth factor. Pediatr Res 1985; 19: 879-86.
14. Lind L, Andersson PE, Andren B, Hanni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13: 433-8.
15. Costa CH, Batista MC, Moises VA, Kohlmann NB, Ribeiro AB, Zanella MT. Serum insulin levels, 24-hour blood pressure profile, and left ventricular mass in nonobese hypertensive patients. Hypertension 1995; 26: 1085-8.
16. Kamide K, Nagano M, Nakano N et al. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 1996; 9: 1165-71.
17. Malmqvist K, Isaksson H, Östergren J, Kahan T. Left ventricular mass is not related to insulin sensitivity in never-treated primary hypertension. J Hypertens 2001; 19: 311-7.
18. Sundström J, Lind L, Nyström N et al. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation 2000; 101: 2595-600.
19. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-14.
20. Hirose H, Saito I, Tsujioka M, Mori M, Kawabe H, Saruta T. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. J Hypertens 1998; 16: 2007-12.
21. Paolisso G, Tagliamonte MR, Galderisi M et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999; 34: 1047-52.
22. Devereux RB, Casale PN, Kligfield P et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 1986; 57: 1388-93.
23. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy, prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7-13.
24. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-84.
25. Malmqvist K, Kahan T, Edner M et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-76.
26. Nyström FMK, Malmqvist K, Öhman KP, Kahan T. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension. J Hypertens 2002; 20: 1527-34.
27. Fyhrquist F, Soveri P, Puutula L, Stenman UH. Radioimmunoassay of plasma renin activity. Clin Chem 1976; 22: 250-6.
28. Buttery JE, Stuart S. Assessment and optimization of kinetic methods for angiotensin-converting enzyme in plasma. Clin Chem 1993; 39: 312-6.
29. McKenzie JK. Clements JA. Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity. J Clin Endocrinol Metab 1974; 38: 622-7.
30. Hjemdahl P. Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. Meth Enzymol 1987; 142: 521-34.
31. Eriksson BM, Wikström M. Determination of catecholamines in urine by liquid chromatography and electrochemical detection after on-line sample purification on immobilized boronic acid. J Chromatogr 1992; 593: 185-90.
32. Hemmila I, Dakubu S, Mukkala VM, Siitari H, Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Anal Biochem 1984; 137: 335-43.
33. Andersen L, Dinesen B, JÖrgensen PN, Poulsen F. Röder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 39: 578-82.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment, insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
35. Ilercil A, O'Grady MJ, Roman MJ et al. Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. J Am Soc Echocardiogr 2001; 14: 601-11.
36. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 564-9.
37. Thürmann PA, Kenedi P, Schmidt A, Harder S. Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-42.
38. Duprez DA, Bauwens FR, De Buyzere ML et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71: 17-20.
39. Harrap SB, Dominiczak AF, Fraser R et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93: 1148-54.
40. Muscholl MW, Schunkert H, Muders F et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J 1998; 135: 58-66.
41. Rossi MA, Pathologic fibrosis and connective tissue matrix in leff ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031-41.
42. Esler M, Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst 1998; 72: 210-9.
43. Schroeder AP, Sihm I, Morn B, Thygesen K, Pedersen EB, Lederballe O. Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives. Am J Hypertens 1996; 9: 207-15.
44. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999; 17: 719-34.
45. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest 1983; 72: 732-8.
46. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension. A meta-analysis. Arch Intern Med 1992; 152: 1649-51.
47. Verdecchia P, Reboldi G, Schillaci G et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100: 1802-7.
48. Lansang MC, Williams GH, Carroll JS. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens 2001; 14: 51-3.
49. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
50. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81.
51. Shimamoto K, Hirata A, Fukuoka M et al. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994; 23: I29-33.
52. Agata J, Masuda A, Takada M et al. High plasma immuno-reactive leptin level in essential hypertension. Am J Hypertens 1997; 10: 1171-4.
53. Nyström F, Ekman B, Österlund M, Lindström T, öhman KP, Arnqvist HJ. Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clin Endocrinol (Oxf) 1997; 47: 191-8.
54. Kennedy A, Gettys TW, Watson P et al. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 1997; 82: 1293-300.
55. Leyva F, Godsland IF, Ghatei M et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998; 18: 928-33.
56. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270-8.